-
The authors performed a nested case-control study using data from the Rochester Epidemiology Project which conducts population-based studies of the residents of Olmsted County, Minnesota.
-
In this issue: Lorcaserin for weight loss; statins and fatigue; treatment-resistant gonorrhea; hydrocodone classification changes; USPSTF recommendations; and FDA actions.
-
Apropos of the recent emphasis on discouraging elective deliveries prior to 39 weeks, a group from Cincinnati embarked on a study to determine whether steroids had any neonatal benefit in patients delivering between 34 and 39 weeks who had immature amniotic fluid lung profiles.
-
The authors performed a prospective cohort study, the contraceptive CHOICE Project, in which women in the St. Louis, Missouri, region received a reversible contraceptive method of their choice for up to 3 years at no cost.
-
Public health officials are sounding the alarm on the growing threat of multi-drug resistant gonorrhea. What will it take to turn the tide against gonorrhea, the second most commonly reported communicable disease in the United States?
-
Another oral contraceptive (OC) packaging alert has been issued. Check your clinic's stock for norgestimate and ethinyl estradiol birth control pills distributed by Glenmark Generics.
-
African-American women at risk for HIV are the focus of a new prevention program launched by the Centers for Disease Control and Prevention (CDC). "Take Charge. Take the Test" is running in 10 cities where such women are especially hard-hit by the disease.
-
Clinicians and researchers now have more comprehensive parameters to assess the stages of menopause with updated criteria known as the Stages of Reproductive Aging Workshop +10 (STRAW +10).
-
With relatively few contraindications to use, progestin-only pills might be a possible candidate for over-the-counter (OTC) use in the United States. But what will it take to move progestin-only pills to the drugstore shelves?
-
Reaching young people with an HIV prevention message is important: The Centers for Disease Control and Prevention (CDC) estimates young people ages 13-29 accounted for 39% of all new HIV infections in 2009.